First National Financial Corporation Announces July Dividend Payment
TORONTO, July 16, 2018 /CNW/ - First National Financial Corporation (TSX: FN) today announced its monthly dividend payment of $0.154167 per common share for the period July 1 to July 31, 2018. The dividend will be payable on August 15, 2018 to shareholders of record at the close of business on July 31, 2018.
About First National Financial Corporation First National Financial Corporation (TSX: FN, TSX: FN.PR.A, TSX: FN.PR.B) is the parent company of First National Financial LP, a Canadian-based originator, underwriter and servicer of predominantly prime residential (single-family and multi-unit) and commercial mortgages. With more than $100 billion in mortgages under administration, First National is Canada's largest non-bank originator and underwriter of mortgages and is among the top three in market share in the mortgage broker distribution channel. For more information, please visit www.firstnational.ca.
Victoria Gold Corp. ("Victoria" or the "Company") held its Annual General Meeting (the "Meeting") earlier today, May 10, 2024, in Vancouver, British Columbia. Shareholders voted in favour of all items proposed by the board of directors and...
GINSMS Inc. (the "Corporation") has announced its financial results for the first quarter ended March 31, 2024. The complete financial results for GINSMS are available at www.sedar.com. Highlights include: Revenue of $710,305 for the three-month...
Karnalyte Resources Inc. ("Karnalyte" or the "Company") today announced its financial results and corporate highlights for the first quarter ended March 31, 2024.
Q1 2024 HIGHLIGHTS
The Company continued to make progress on its NI 43-101 compliant...
PHX Energy Services Corp. ("PHX Energy") is pleased to announce the voting results for the election of directors at its annual meeting of shareholders held on May 10, 2024 (the "Meeting"). The following seven nominees were elected as directors of PHX...
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...
